# OnCo record fluid-retention-and-effusions-on-kinase-inhibitors (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "fluid-retention-and-effusions-on-kinase-inhibitors" ;
  schema:name "Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs"@en ;
  schema:alternateName "oedema on targeted therapy"@en, "edema on TKIs"@en, "periorbital oedema on imatinib"@en, "puffy eyes on imatinib"@en, "swollen legs on capmatinib"@en, "MET inhibitor oedema"@en, "dasatinib pleural effusion"@en, "fluid retention on imatinib"@en ;
  schema:description "Some targeted cancer drugs make the body hold on to fluid: puffy eyelids, swollen ankles or, with dasatinib, fluid around the lungs. Swelling is managed with raised legs, support stockings, less salt, sometimes water tablets, and a lower dose if needed. Tell your cancer team promptly about rapid weight gain, new breathlessness, a dry cough, chest pain or one swollen, painful leg."@en ;
  schema:url <https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/lymphoedema-risk-reduction-surveillance-and-treatment/>, <https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/>, <https://onco.cc/protocols/differentiation-syndrome-recognition-and-treatment/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/vimseltinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:terms <https://onco.cc/terms/ctcae-grading/>, <https://onco.cc/terms/vte/> .
